News – Page 913 – Endpoints News

Regulators throw up another hurdle to Roche’s $4.3B Spark acquisition as questions percolate over hemophilia market ...

6 years ago

Coming out of Chapter 11, Aegerion jumps into welcome arms of Irish pharma with big plans, fresh $60M for its drugs

6 years ago

Novartis accuses 2 AveXis founders of altering data, stonewalling probe — but ex-CSO blasts back

6 years ago

Eli Lilly dishes out first milestone payment for Alzheimer's deal; ADC Therapeutics, Viela Bio set terms for IPO

6 years ago

Hypoglycemia 'Epipen' clears Phase III, hurtles toward FDA decision

6 years ago

Cerevel plots first late-stage move as Pfizer drug comes through in PhII Parkinson's trial

6 years ago

UroGen steers towards its first commercial drug launch, armed with strong data on lead therapy

6 years ago

Bay Area biotech hauls in $62M to pay the freight on early-stage CD33/CD3 T cell engager

6 years ago

Embattled AMAG braces for October FDA Makena adcom, but it need not worry — analyst

6 years ago

Is Regeneron losing its R&D mystique? Analyst discounts big biotech’s runner-up development strategy in an ...

6 years ago

Startup EPM launches, high off cannabinoid acid innovation

6 years ago

Ex-Retrophin BD chief flips his rare disease startup onto Nasdaq via reverse merger with Proteon

6 years ago

Lundbeck’s Deborah Dunsire didn’t just want an ex-US deal for Alder’s migraine drug. She wanted the whole world

6 years ago

GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union

6 years ago

Servier begins manslaughter trial over weight loss drug

6 years ago

Once touted as Lyrica rival for diabetic nerve pain, Korean biotech's plasmid product implodes in PhIII

6 years ago

AstraZeneca vet heads to UK biotech as the new CSO; Mallinckrodt touts positive PhIII data

6 years ago

FDA puts the brakes on a rare disease biotech’s PhIII as regulators wait for an update — shares crumble

6 years ago

Deepening US footprint, AstraZeneca-partnered French biotech Innate shoots for $100M IPO

6 years ago

Akcea’s top 3 C-suite execs are chopped out as Ionis sends in an interim quarterback from their bench

6 years ago

Amid Woodford debacle, Immunocore cuts valuation as it secures $74M from General Atlantic — report

6 years ago

New Flagship biotech wants to unleash your genome

6 years ago

A long-suffering Clovis makes a leap into radiopharmaceuticals, paying $12M in cash to beef up the pipeline

6 years ago

Here comes the oral GLP-1 drug for diabetes — and Novo Nordisk wants to price Rybelsus 'at a similar level as ...

6 years ago

First page Previous page 910 911 912913914 915 916 Next page Last page